Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data

 
• By Alaric DeArment
Merck announced results for Welireg in renal cell carcinoma after checkpoint inhibitor and anti-VEGF treatment • Source: Shutterstock

More from Clinical Trials

More from R&D